Alert: FTC Challenges "No-AG" Agreement as Illegal Reverse Payment

by Cooley LLP

On March 30 the US Federal Trade Commission filed suit in federal court alleging that settlements of patent litigation in the pharmaceutical industry in which a pioneer firm agrees not to market an "authorized generic" violate antitrust law.

The FTC is seeking disgorgement of what it alleges are "ill-gotten gains" from Endo Pharmaceuticals, Inc. and a number of generic firms in the agency's second suit challenging patent litigation settlements since the Supreme Court's decision in FTC v. Actavis, which declared settlements with so-called "reverse-payments" to be potentially unlawful.

The lawsuit underscores the FTC's view that Actavis should apply to non-cash forms of payment, including agreements by pioneer manufacturers not to introduce an authorized generic during the 180 days that the Hatch-Waxman Act prohibits the FDA from approving another generic ("no-AG" agreements). It also serves as a reminder that the FTC remains active in scrutinizing settlements of patent litigation and bringing enforcement actions.

Analytical framework applied to reverse payments: FTC v. Actavis

For years, the FTC has sought to end so-called "reverse payment" settlements in which parties resolve Hatch-Waxman litigation on terms that allow a generic drug to enter at some future date before the patent at issue would expire were the pioneer to win the lawsuit. The FTC views such payments as "payments for delay," arguing that the parties would have agreed to an earlier entry date in the absence of a payment.

In 2013, the Supreme Court set forth the framework that courts now use to determine whether reverse payments violate antitrust law. In FTC v. Actavis, the Court held that settlement agreements with reverse payments should be evaluated under the "rule of reason," and may be illegal when payments are "large and unjustified." The Court reasoned that the "likely anticompetitive effects" and "potential justifications" can be assessed by examining the size of a payment, taking the view that "[a]n unexplained large reverse payment itself would normally suggest that the patentee has serious doubts about the patent's survival." At the same time, the Court noted that where a reverse payment reflects "traditional settlement considerations" such as "avoided litigation costs" or "fair value for services," there is not the same concern.

Post-Actavis, several issues remain unresolved, including how to determine what constitutes a large payment, how one judges whether a side-deal is for fair value, and whether Actavis modifies the causation standard that applies to private plaintiffs.

Application of Actavis to no-AG agreements

The FTC has actively advocated for the application of Actavis to "no-AG" agreements through both speeches and amicus briefs. It argued in an amicus brief in 2012, for instance, that a "no-AG commitment provides a convenient method for branded drug firms to pay generic patent challengers for agreeing to delay entry," given that "the economic realities of a no-AG commitment are that it provides significant value to a first-filer generic company."

While some district courts initially concluded that Actavis did not reach no-AG agreements, most courts, including the Third Circuit, have determined that Actavis applies with equal force to non-cash forms of consideration, including no-AG agreements. In King Drug v. SmithKline Beecham, the Third Circuit reasoned that "no-AG agreements are likely to present the same types of problems as reverse payments of cash" given the "great monetary value" that a no-AG agreement represents to the generic. The defendants have submitted a petition for certiorari to the Supreme Court, arguing that the Third Circuit's decision expanded Actavis "well beyond its intended bounds," improperly infringing on patent holders' rights to grant licenses, including exclusive licenses.

The FTC's most recent reverse payment challenge

In FTC v. Endo, the FTC is challenging allegedly "anticompetitive reverse-payment agreements orchestrated by Endo" to prevent generic competition to what the FTC characterized as its "two most important branded prescription drug products": Opana ER, an opioid drug, and Lidoderm, a lidocaine patch.

The FTC is challenging three types of payments: (1) Endo's agreement not to offer a competing authorized generic, (2) a development and co-promotion agreement with the generic manufacturer of Opana that the FTC alleges "made no [independent] business or economic sense" for Endo, and (3) a distribution agreement with the generic manufacturer of Lidoderm under which the FTC asserts Endo supplied the drug "at no cost."

The FTC is seeking "restitution or disgorgement, to redress and prevent recurrence of defendants' violations," in addition to injunctive relief. This follows a trend in recent reverse payment cases in which the FTC has sought disgorgement.

In a statement issued with the complaint, FTC Chairwoman Edith Ramirez argues, "[s]ettlements between drug firms that include 'no-AG commitments' harm consumers twice – first by delaying the entry of generic drugs and then preventing additional generic competition in the market following generic entry. This lawsuit reflects the FTC's commitment to stopping pay-for-delay agreements that inflate the prices of prescription drugs and harm competition, regardless of the form they take."

The FTC simultaneously filed a stipulated order for permanent injunction with one firm, prohibiting it from engaging in certain reverse-payment agreements, including no-AG commitments, for 20 years. Interestingly, that settlement does not include any monetary relief.

Commissioner Maureen Ohlhausen dissented from the FTC's decision to file suit in federal court, taking the position that disgorgement in this case is not in the public interest and that the Commission should have pursued the matter administratively. She agreed, however, that there was "reason to believe that the Defendants violated" the law. She argued that an administrative suit "would allow the Commission to render a thoughtful decision applying the Actavis standard, providing much-needed guidance to courts and firms around the country."

The FTC continues to scrutinize reverse payment settlement agreements

Numerous private antitrust suits challenging settlements of patent litigation have been filed in recent years, and the FTC has weighed-in with amicus briefs, leading some to speculate that the FTC might be stepping back its case enforcement.

With this latest suit, the FTC has now filed two suits since the Actavis decision, including its September 2014 challenge to allegedly baseless patent litigation as well as a settlement agreement, in FTC v. AbbVie.

In that case, the FTC alleges that the generic manufacturers filed sham lawsuits, and that the branded manufacturer agreed to supply another drug which amounted to a reverse payment. In July 2015, the Eastern District of Pennsylvania dealt the FTC a setback, granting the defendants' partial motion to dismiss, and denying the FTC's request for partial judgment to allow immediate appeal.

The FTC has also continued to pursue reverse payment litigation filed before the Supreme Court's decision in Actavis, including Actavis itself. In June 2015, it reached a landmark $1.2 billion settlement with Teva, stemming from its 2008 lawsuit that alleged that Cephalon (now owned by Teva) paid generic manufacturers to forgo marketing generic Provigil for six years. Teva also agreed to a permanent injunction prohibiting it from engaging in certain types of reverse payment agreements.

While the FTC's complaint may only be the latest development in the reverse payment saga, it confirms that the FTC remains active not just in filing amicus briefs and making public statements (indeed, it has filed three amicus briefs already in 2016), but also in bringing reverse payment enforcement actions. Pharmaceutical companies considering settling patent litigation should therefore carefully weigh the risk of FTC enforcement in addition to private enforcement.

[View source.]

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Cooley LLP | Attorney Advertising

Written by:

Cooley LLP

Cooley LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.